Sana Biotechnology (NASDAQ:SANA) Upgraded by TD Cowen to Strong-Buy Rating

Posted by Francis Steltz on Aug 25th, 2026

Sana Biotechnology (NASDAQ:SANA – Get Free Report) was upgraded by TD Cowen to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Several other equities research analysts also recently commented on the stock. Wall Street Zen downgraded shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Bank of America decreased their price target on shares of Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a report on Friday, August 14th. Rodman & Renshaw started coverage on Sana Biotechnology in a research note on Monday, May 11th. They set a “buy” rating and a $16.00 price objective on the stock. Finally, Weiss Ratings upgraded Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $9.33.

Read Our Latest Research Report on SANA

Sana Biotechnology Trading Down 3.3%

Sana Biotechnology stock opened at $3.78 on Monday. The firm has a market capitalization of $1.13 billion, a P/E ratio of -4.97 and a beta of 2.16. Sana Biotechnology has a 1 year low of $2.61 and a 1 year high of $6.55. The business has a 50-day moving average of $3.49 and a 200-day moving average of $3.41.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. Research analysts anticipate that Sana Biotechnology will post -0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SANA. AQR Capital Management LLC increased its stake in Sana Biotechnology by 49.8% in the 1st quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock valued at $963,000 after buying an additional 190,483 shares during the last quarter. Woodline Partners LP boosted its stake in shares of Sana Biotechnology by 13.1% during the 1st quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock worth $1,312,000 after buying an additional 90,515 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Sana Biotechnology by 86.8% in the 2nd quarter. Franklin Resources Inc. now owns 93,081 shares of the company’s stock valued at $254,000 after acquiring an additional 43,247 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Sana Biotechnology by 11.6% in the 2nd quarter. Rhumbline Advisers now owns 203,283 shares of the company’s stock valued at $555,000 after acquiring an additional 21,149 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new stake in shares of Sana Biotechnology in the second quarter valued at about $50,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

(Get Free Report)

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.